Le Lézard
Classified in: Ebola virus, Health, Science and technology, Covid-19 virus
Subject: MRR

Global Messenger RNA (mRNA) Vaccines & Therapeutics Markets, 2022-2023 & 2028: Rising Demand for Therapeutic Drugs and Vaccines for Ebola, influenza, HIV, and Other Viral Illnesses


DUBLIN, Jan. 6, 2023 /PRNewswire/ -- The "Messenger RNA (mRNA) Vaccines & Therapeutics Market, Size, Global Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Research_and_Markets_Logo

Global Messenger RNA (mRNA) Vaccines and Therapeutics Market was valued at US$ 11.63 Billion in 2022 and is expected to reach US$ 26.34 Billion by 2028

Messenger Ribonucleic Acid (mRNA) is a term that refers to a single protein-coding gene in the genome that conforms as the basis for protein synthesis in cells. mRNA vaccines and treatments are made in laboratories utilizing mammalian cells and have favorable immunological characteristics.

Infection prevention mRNA vaccines, infectious disease treatment mRNA vaccines, customized cancer therapy mRNA vaccines, and standardization of cancer treatment mRNA vaccines are frequent types of vaccinations and therapies. They are injected into the body to activate virus-detecting immunological sensors and cause the cells to generate viral antigen proteins. This improves B- and T-cell responses, which helps the body's immunity.

Global Messenger RNA (mRNA) Vaccines & Therapeutics Market Size will expand at a CAGR of 14.60% from 2022 to 2028

mRNA vaccines and treatments are generated employing new technologies that are more effective against infections, have higher potency, improved immunogenicity, and are relatively more cost-effective than conventional pharmaceuticals.

One of the critical factors propelling the development of the Global Messenger RNA (mRNA) Vaccines & Therapeutics Market is the increased prevalence of medical disorders such as diabetes, TB, cancer, and cardiovascular diseases (CVDs).

In addition, the industry also benefits from rising demand for therapeutic drugs and vaccines for Ebola, influenza, HIV, and other viral illnesses.

Evolution of the Global Messenger RNA (mRNA) Vaccines & Therapeutics Industry amidst Pandemic

With the launch and widespread usage of mRNA vaccines and therapies for COVID-19, 2020 marked a watershed moment for mRNA technology platforms. As a result, the combined market valuation of mRNA platforms had increased fast by 2020.

The increase in market value reflects expectations that mRNA technology will give far more than the current COVID-19 preventive vaccines.

Global Messenger RNA (mRNA) Vaccines & Therapeutics Market Segmentation Analysis:

By Type, the market is bifurcated into Infection Prevention mRNA Vaccine, Infectious Disease Treatment mRNA Vaccine, Individualized Cancer Treatment mRNA Vaccine, and Standardization of Cancer Treatment mRNA Vaccine.

By Application, Cancer, Infectious Diseases, and Others are the major segments covered in our report. As per our estimates, Infectious Diseases hold a significant share in the market and are estimated to remain dominant throughout the forecasted period.

By End User, we have studied the market for hospitals, Clinics, Diagnostics Centers, and Others. As per our analysis, clinics and diagnostic centers are gaining traction with the advancement of technology applications. However, hospitals tend to remain dominant throughout the study period.

By Region, North America, Europe, Asia-Pacific, and Rest of the World. During the forecast period, North America is estimated to monopolize the Global Messenger RNA (mRNA) Vaccines & Therapeutics Market. The market in North America is contrived by an increase in demand for COVID-19 mRNA vaccines, major players operating in the US, and an exponential rise in the number of COVID-19 cases in the US.

Key Players:

Pfizer, GlaxoSmithKline, Daiichi Sankyo Company, Limited, Intellia Therapeutics, Moderna Inc, CureVac N.V., Arcturus Therapeutics Holdings, and BioNTech are the prominent companies in the Global Messenger RNA (mRNA) Vaccines & Therapeutics Market examined in our analysis.

In addition, we have discussed the competition landscape section of the study, which included an overview, the latest development strategies, and market revenue analysis of the above-mentioned worldwide companies. Surprisingly, the major firms invest in mRNA technologies since they can integrate numerous molecules into a therapeutic drug, which is a huge growth factor.

Key Players:

Company Insights:

Key Topics Covered:

1. Introduction

2. Research& Methodology

3. Executive Summary

4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
4.3 Opportunities

5. Global Messenger RNA (mRNA) Vaccines & Therapeutics Market

6. Share Analysis - Global Messenger RNA (mRNA) Vaccines & Therapeutics Market
6.1 By Type
6.2 By Application
6.3 By End User
6.4 By Region

7. Type - Global Messenger RNA (mRNA) Vaccines & Therapeutics Market
7.1 Infection Prevention mRNA Vaccine
7.2 Infectious Disease Treatment mRNA Vaccine
7.3 Individualized Cancer Treatment mRNA Vaccine
7.4 Standardization of Cancer Treatment mRNA Vaccine

8. Application - Global Messenger RNA (mRNA) Vaccines & Therapeutics Market
8.1 Cancer
8.2 Infectious Diseases
8.3 Others

9. End User - Global Messenger RNA (mRNA) Vaccines & Therapeutics Market
9.1 Hospital
9.2 Clinics
9.3 Diagnostics Centers
9.4 Others

10. Region - Global Messenger RNA (mRNA) Vaccines & Therapeutics Market
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Rest of the World

11. Key Players

For more information about this report visit https://www.researchandmarkets.com/r/l4smrn

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets


These press releases may also interest you

21 mar 2019
The "Europe Welding Equipment Market-Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering. Welding is one of the critical processes employed in the manufacturing...

21 mar 2019
Inovio Pharmaceuticals, Inc. announced today that its Ebola vaccine, INO-4201, was safe, tolerable, and generated strong T cell and antibody responses. This Phase 1 data was published in The Journal of Infectious Diseases and further supports the...

20 mar 2019
Merck , known as MSD outside the United States and Canada, and NGM Biopharmaceuticals, Inc. (NGM) today announced that Merck has exercised its option to extend the research phase of the companies' broad, strategic collaboration...

20 mar 2019
The shareholders in Sandvik Aktiebolag are convened to the Annual General Meeting to be held on Monday, 29 April 2019 at 3:00 p.m. at the Göransson Arena, Sätragatan 21, Sandviken, Sweden. RIGHT TO PARTICIPATE AND NOTICE Shareholders who wish to...

20 mar 2019
The Oslo Business for Peace Award is given to inspiring business leaders who have put society first. 2019's winners are: Dr Agbor Ashumanyi Ako, medical director of GiftedMom, Alice Laugher, CEO of Committed to...

19 mar 2019
The evolving competitive market has made it essential for the telecommunication industry to rethink traditional ways of doing business in terms of the impact on business models, service portfolios and technical architectures. Digital business support...



News published on and distributed by: